184 related articles for article (PubMed ID: 15530176)
1. The importance of parathyroid hormone and vitamin D status in the treatment of osteoporosis and renal insufficiency.
Drinka PJ
J Am Med Dir Assoc; 2004; 5(6):382-6. PubMed ID: 15530176
[TBL] [Abstract][Full Text] [Related]
2. The importance of parathyroid hormone and vitamin D status in the treatment of osteoporosis and renal insufficiency.
Drinka PJ
J Am Med Dir Assoc; 2006 Mar; 7(3 Suppl):S5-9, 4. PubMed ID: 16500280
[TBL] [Abstract][Full Text] [Related]
3. Relation between circulating levels of 25(OH) vitamin D and parathyroid hormone in chronic kidney disease: quest for a threshold.
Metzger M; Houillier P; Gauci C; Haymann JP; Flamant M; Thervet E; Boffa JJ; Vrtovsnik F; Froissart M; Stengel B; Ureña-Torres P;
J Clin Endocrinol Metab; 2013 Jul; 98(7):2922-8. PubMed ID: 23633202
[TBL] [Abstract][Full Text] [Related]
4. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors?
Anderson JL; Vanwoerkom RC; Horne BD; Bair TL; May HT; Lappé DL; Muhlestein JB
Am Heart J; 2011 Aug; 162(2):331-339.e2. PubMed ID: 21835295
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D deficiency and primary hyperparathyroidism.
Nuti R; Merlotti D; Gennari L
J Endocrinol Invest; 2011 Jul; 34(7 Suppl):45-9. PubMed ID: 21985980
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral metabolism and its relationship to kidney disease in a residential care home population: a cross-sectional study.
Carter JL; O'Riordan SE; Eaglestone GL; Delaney MP; Lamb EJ
Nephrol Dial Transplant; 2008 Nov; 23(11):3554-65. PubMed ID: 18544628
[TBL] [Abstract][Full Text] [Related]
7. Relationship between vitamin D status, parathyroid hormone levels and bone mineral density in patients with chronic kidney disease stages 3 and 4.
Stavroulopoulos A; Porter CJ; Roe SD; Hosking DJ; Cassidy MJ
Nephrology (Carlton); 2008 Feb; 13(1):63-7. PubMed ID: 18199106
[TBL] [Abstract][Full Text] [Related]
8. Secondary hyperparathyroidism in primary osteoporosis and osteopenia: optimizing calcium and vitamin D intakes to levels recommended by expert panels may not be sufficient for correction.
Yendt ER; Kovacs KA; Jones G
Clin Endocrinol (Oxf); 2008 Dec; 69(6):855-63. PubMed ID: 18419790
[TBL] [Abstract][Full Text] [Related]
9. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
10. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low.
Ennis JL; Worcester EM; Coe FL; Sprague SM
J Nephrol; 2016 Feb; 29(1):63-70. PubMed ID: 25736620
[TBL] [Abstract][Full Text] [Related]
11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D, parathyroid hormone, and bone mineral density status in kidney transplant recipients.
Savaj S; Ghods FJ
Iran J Kidney Dis; 2012 Jul; 6(4):295-9. PubMed ID: 22797100
[TBL] [Abstract][Full Text] [Related]
13. [Review of the concept of vitamin D "sufficiency and insufficiency"].
Gómez Alonso C; Naves Díaz M; Rodríguez García M; Fernández Martín JL; Cannata Andía JB
Nefrologia; 2003; 23 Suppl 2():73-7. PubMed ID: 12778859
[TBL] [Abstract][Full Text] [Related]
14. Cholecalciferol supplementation in chronic kidney disease: restoration of vitamin D status and impact on parathyroid hormone.
Garcia-Lopes MG; Pillar R; Kamimura MA; Rocha LA; Canziani ME; Carvalho AB; Cuppari L
Ann Nutr Metab; 2012; 61(1):74-82. PubMed ID: 22889840
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for secondary hyperparathyroidism in a nursing home population.
Stein MS; Scherer SC; Walton SL; Gilbert RE; Ebeling PR; Flicker L; Wark JD
Clin Endocrinol (Oxf); 1996 Apr; 44(4):375-83. PubMed ID: 8706303
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications.
Lips P
Endocr Rev; 2001 Aug; 22(4):477-501. PubMed ID: 11493580
[TBL] [Abstract][Full Text] [Related]
17. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
18. Challenges in the therapy of secondary hyperparathyroidism.
Wood C; González EA; Martin KJ
Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
[TBL] [Abstract][Full Text] [Related]
19. [K/DOQI clinical practice guidelines for management of renal osteodystrophy in predialysis patients].
Okada N; Tsubakihara Y
Clin Calcium; 2004 May; 14(5):698-706. PubMed ID: 15577030
[TBL] [Abstract][Full Text] [Related]
20. The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects.
Lips P; Wiersinga A; van Ginkel FC; Jongen MJ; Netelenbos JC; Hackeng WH; Delmas PD; van der Vijgh WJ
J Clin Endocrinol Metab; 1988 Oct; 67(4):644-50. PubMed ID: 3417845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
